These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

203 related articles for article (PubMed ID: 19391232)

  • 1. Sitagliptin combined with sulphonylureas: new indication. Other treatments are preferable.
    Prescrire Int; 2009 Feb; 18(99):14-5. PubMed ID: 19391232
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Sitagliptin + metformin: new combination. Do not use this combination. Sitagliptin provides a slight increase of glucose-lowering effects, but there is a disturbing potential for long-term adverse effects: infections, depression, and cancer.
    Prescrire Int; 2009 Jun; 18(101):115. PubMed ID: 19637427
    [No Abstract]   [Full Text] [Related]  

  • 3. [Sitagliptin].
    Taéron C
    Rev Infirm; 2008 Oct; (144):46-8. PubMed ID: 19009789
    [No Abstract]   [Full Text] [Related]  

  • 4. Fixed-dose combination therapy for type 2 diabetes: sitagliptin plus pioglitazone.
    Bailey CJ; Green BD; Flatt PR
    Expert Opin Investig Drugs; 2010 Aug; 19(8):1017-25. PubMed ID: 20629618
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Sitagliptin 100 mg daily effect on DPP-4 inhibition and compound-specific glycemic improvement.
    Alba M; Sheng D; Guan Y; Williams-Herman D; Larson P; Sachs JR; Thornberry N; Herman G; Kaufman KD; Goldstein BJ
    Curr Med Res Opin; 2009 Oct; 25(10):2507-14. PubMed ID: 19691426
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Elevated hepatic enzymes potentially associated with sitagliptin.
    Gross BN; Cross LB; Foard J; Wood Y
    Ann Pharmacother; 2010 Feb; 44(2):394-5. PubMed ID: 20103614
    [No Abstract]   [Full Text] [Related]  

  • 7. Low-dose glimepiride with sitagliptin improves glycemic control without dose-dependency in patients with type 2 diabetes inadequately controlled on high-dose glimepiride.
    Umayahara R; Yonemoto T; Kyou C; Morishita K; Ogawa T; Taguchi Y; Inoue T
    Endocr J; 2014; 61(12):1163-70. PubMed ID: 25168659
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effect of the dipeptidyl peptidase-4 inhibitor sitagliptin in older adults with type 2 diabetes mellitus.
    Stafford S; Elahi D; Meneilly GS
    J Am Geriatr Soc; 2011 Jun; 59(6):1148-9. PubMed ID: 21668924
    [No Abstract]   [Full Text] [Related]  

  • 9. Sitagliptin-associated drug allergy: review of spontaneous adverse event reports.
    Desai S; Brinker A; Swann J; Iyasu S
    Arch Intern Med; 2010 Jul; 170(13):1169-71. PubMed ID: 20625027
    [No Abstract]   [Full Text] [Related]  

  • 10. [Incretin strategy in the treatment of type 2 diabetes mellitus--the DPP-IV inhibitor sitagliptin].
    Perusicová J
    Vnitr Lek; 2007 Oct; 53(10):1109-13. PubMed ID: 18072437
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Drug eruption caused by sitagliptin, a dipeptidyl peptidase-IV inhibitor.
    Tanaka K; Ogawa Y; Shimada S
    J Dermatol; 2012 Aug; 39(8):726-8. PubMed ID: 21981936
    [No Abstract]   [Full Text] [Related]  

  • 12. Sitagliptin intolerance.
    Kargili A; Karakurt F; Kankilic MN; Kankilic ES; Bozkurtl B
    Allergol Immunopathol (Madr); 2010; 38(5):290-1. PubMed ID: 20554368
    [No Abstract]   [Full Text] [Related]  

  • 13. [A new therapeutic possibility for type 2 diabetes: DPP-4 inhibitors (sitagliptin)].
    Abel T; Fehér J
    Orv Hetil; 2010 Jun; 151(25):1012-6. PubMed ID: 20519186
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Sitagliptin: a dipeptidyl peptidase IV inhibitor for the treatment of type 2 diabetes.
    Miller S; St Onge EL
    Ann Pharmacother; 2006; 40(7-8):1336-43. PubMed ID: 16868220
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Incretin enhancer: sitagliptin].
    Kondo M; Tanizawa Y
    Nihon Rinsho; 2011 May; 69(5):859-63. PubMed ID: 21595272
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Efficacy and safety of the dipeptidyl peptidase-4 inhibitor sitagliptin compared with α-glucosidase inhibitor in Japanese patients with type 2 diabetes inadequately controlled on sulfonylurea alone (SUCCESS-2): a multicenter, randomized, open-label, non-inferiority trial.
    Kobayashi K; Yokoh H; Sato Y; Takemoto M; Uchida D; Kanatsuka A; Kuribayashi N; Terano T; Hashimoto N; Sakurai K; Hanaoka H; Ishikawa K; Onishi S; Yokote K;
    Diabetes Obes Metab; 2014 Aug; 16(8):761-5. PubMed ID: 24447683
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Drug reaction with eosinophilia and systemic symptoms (DRESS) in a patient taking sitagliptin.
    Sin C; Mahé E; Sigal ML
    Diabetes Metab; 2012 Dec; 38(6):571-3. PubMed ID: 23183246
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Sitagliptin: a review of its use in patients with type 2 diabetes mellitus.
    Plosker GL
    Drugs; 2014 Feb; 74(2):223-42. PubMed ID: 24407560
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Vildagliptin and vildagliptin/metformin: new drug. Same limited efficacy as sitagliptin in type 2 diabetes.
    Prescrire Int; 2008 Oct; 17(97):188. PubMed ID: 19534040
    [No Abstract]   [Full Text] [Related]  

  • 20. Sitagliptin: a review of its use in the management of type 2 diabetes mellitus.
    Dhillon S
    Drugs; 2010 Mar; 70(4):489-512. PubMed ID: 20205490
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.